(See the major article by Castellsagué et al on pages 517–34.)

Scientists do not know precisely which elements of the immune system are important in preventing or resolving human papillomavirus (HPV) infections in unvaccinated women. HPV has a battery of allowed-evasion mechanisms that include hiding inside the host mucosal cells, depression-level production of late (L) proteins, and inhibition of innate immunity and jail cell-mediated response past early proteins [1].

HPV vaccine trials show that sufficiently high levels of neutralizing antibodies against viral capsid strongly protect women who are negative for vaccine types at baseline confronting homologous (aforementioned-blazon) HPV infection. The measurement of HPV antibodies is as well important for identifying unvaccinated women who accept mounted an antibiotic response following previous exposure to HPV infection and may, therefore, be naturally protected. Even so, only approximately half of women seroconvert within 18 months after HPV infection [ii]. The interpretation of HPV serology is additionally complicated by substantial differences across assays used in different studies (eg, detection ranges, targeted HPV types, and epitopes) [iii–5]. Despite these limitations, seroprevalence studies have been essential in agreement HPV exposure [half dozen] and infection trends [vii], and take more than recently started providing prospective estimates of naturally caused amnesty after HPV infection [4].

In this upshot of The Journal of Infectious Diseases, Castellsagué and colleagues [eight] written report on the association of HPV types sixteen and xviii antibody levels and the development of new homologous HPV infections and cervical lesions in >8000 women (15–25 years of age) who comprised the control arm of a multinational randomized trial of the HPV-16/eighteen vaccine (PATRICIA). Findings are based on a virus-like particle (VLP)–based enzyme-linked immunosorbent assay (ELISA) that measures a wide spectrum of neutralizing and nonneutralizing antibodies directed against the L1 capsid protein. High titers of HPV-16 antibodies, just non of HPV-18 antibodies, were significantly associated with a lower risk of incident and persistent homologous blazon infection, and also with a lower gamble of singular squamous cells of undetermined significance (ASCUS) and cervical intraepithelial neoplasia (CIN) grades ane–3. Compared with HPV-xvi–seronegative women, new incident HPV-16 infections were reduced by 36% (95% conviction interval [CI], 22%–47%) in HPV-16–seropositive women (ie, 15% of unvaccinated women). Protection significantly increased with the increase in HPV-sixteen antibiotic titer; it was 66% (95% CI, 46%–79%) in the highest HPV-xvi antibiotic quartile [eight].

In the command arm of the Costa Rica Vaccine Trial, Safaeian et al [4] used the same VLP ELISA as Castellsagué et al [8] and reported the same seroprevalence (25%) at enrollment for HPV-16 and HPV-18. A meaning reduction of new homologous blazon infections was observed in the highest tertile of HPV-sixteen and HPV-18 antibodies—protection of 50% and 64%, respectively.

Naturally acquired protection in older women was assessed in a population-based cohort study (median age, 37 years), also from Costa Rica [9], using a different VLP ELISA than the 2 vaccine trials [four, 8]. Seroprevalence at enrollment was nineteen% and 18% for HPV-sixteen and HPV-18, respectively. A significant protection (46%) from subsequent homologous infection was shown for HPV-16 but not HPV-eighteen.

A few studies [3, 9, ten], including that by Castellsagué et al [viii], raised the possibility that serological response to HPV-16 and HPV-18 in women might not be the aforementioned. In fact, some studies showed similar seroprevalence of the two types in the full general female person population despite the consistently higher prevalence of HPV-sixteen Deoxyribonucleic acid than HPV-18 DNA in vaginal samples [3, x]. The evaluation of natural protection against HPV-xviii is farther complicated by the rarity of HPV-xviii–related clinical endpoints, including ASCUS and all grades of CIN [11].

Data on naturally caused protection to HPV infection in males is much more limited than in females. HPV-16 incidence did not differ significantly by HPV-xvi serostatus in a cohort of adult men [12] in whom the same VLP ELISA equally in Wentzensen et al [ix] was used. In fact, higher HPV seroprevalence has been consistently reported for different HPV types in women than men from the same source population [6, thirteen]. The observed divergence by sex in allowed response may be related to the tissues predominantly afflicted by HPV infection between the 2 sexes, that is, mucous membranes in the female genital tract vs keratinized epithelia in the male genital tract.

From a practical viewpoint, Castellsagué et al [viii] contribute, together with some previous work, to fill a knowledge gap that hampers projections on the affect of HPV vaccination from dynamic manual models. In the lack of sufficient data on naturally acquired protection, models published betwixt 2002 and 2013 have assumed different patterns including complete lifelong immunity [14–19] and no natural immunity [17–24]. Partial immunity [xix, 25–27] or waning of immunity [24, 28–32] has also been hypothesized, as well equally boosting of immunity past repeated HPV infections [33] (Table one).

Tabular array 1.

Human Papillomavirus Transmission Models by Assumptions on Blueprint of Naturally Caused Protection

Degree of Protection Duration of Protection No. of Models References
Consummate Lifelong 6 [14–xix]
Waning vi [24, 28–32]
Fractional Lifelong 4 [nineteen, 25–27]
Increasing with historic period 1 [33]
None … 8 [17–24]
Degree of Protection Elapsing of Protection No. of Models References
Consummate Lifelong vi [14–19]
Waning 6 [24, 28–32]
Partial Lifelong 4 [19, 25–27]
Increasing with age 1 [33]
None … 8 [17–24]

Table ane.

Human Papillomavirus Transmission Models past Assumptions on Pattern of Naturally Caused Protection

Caste of Protection Duration of Protection No. of Models References
Complete Lifelong six [14–19]
Waning 6 [24, 28–32]
Partial Lifelong 4 [nineteen, 25–27]
Increasing with age 1 [33]
None … eight [17–24]
Degree of Protection Duration of Protection No. of Models References
Complete Lifelong 6 [fourteen–19]
Waning 6 [24, 28–32]
Partial Lifelong four [nineteen, 25–27]
Increasing with age 1 [33]
None … 8 [17–24]

The existence and the magnitude of naturally caused protection confronting homologous HPV reinfection are crucial to assess the effectiveness of vaccinating sexually active young women [24, 34] and boys in add-on to adolescent girls [eighteen, xix, 25, 26]. If naturally caused protection is absent or weak, vaccination of sexually active young women would be bonny because of the large fraction of them who may nonetheless be susceptible to HPV infection despite having been already infected and having cleared the infection in the by. Similarly, the existence of a large pool of susceptible men despite previous HPV infection would phone call for vaccination of boys in order to reduce the circulation of the virus in a population and eventually reach a desirable herd immunity threshold, that is, a fraction of protected individuals that tin even prevent the infection from spreading to unvaccinated people [35].

In conclusion, the findings from Castellsagué et al [8] show that approximately 1 of 7 young unvaccinated women in the PATRICIA trial has some protection from HPV-sixteen infection because of naturally acquired antibodies. Information technology is impossible, at the moment, to say if all HPV-xvi–seropositive women benefit from a fractional protection from HPV-16 reinfection or if approximately ane-third of them benefit from full naturally acquired amnesty. This proportion may be different in older women; for example, it may be larger if they had had more time or chances to seroconvert or smaller if they tended to lose HPV antibodies. Naturally caused immunity has non been demonstrated in men. Better understanding of these phenomena is crucial to model the effectiveness of different vaccination strategies.

Notes

Financial support.  This piece of work was supported by the Pecker & Melinda Gates Foundation (grant number OPP1053353) and the European Commission's Seventh Framework plan (FP7/2007–2013) under grant agreement No. 603019 (acronym CoheaHr).

Potential conflicts of interest.  Both authors: No reported conflicts.

Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Involvement. Conflicts that the editors consider relevant to the content of the manuscript accept been disclosed.

References

1

Tindle

RW

.

Allowed evasion in man papillomavirus-associated cervical cancer

,

Nature Rev Cancer

,

2002

, vol.

2

 (pg.

59

-

65

)

ii

Carter

JJ

,

Koutsky

LA

,

Hughes

JP

, et al.

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

,

J Infect Dis

,

2000

, vol.

181

 (pg.

1911

-

ix

)

3

Schiffman

M

,

Safaeian

G

,

Wentzensen

Northward

.

The utilize of human papillomavirus seroepidemiology to inform vaccine policy

,

Sex Transm Dis

,

2009

, vol.

36

 (pg.

675

-

9

)

4

Safaeian

1000

,

Porras

C

,

Schiffman

Thou

, et al.

Epidemiological report of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

,

J Natl Cancer Inst

,

2010

, vol.

102

 (pg.

1653

-

62

)

5

Lin

SW

,

Ghosh

A

,

Porras

C

, et al.

HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays

,

PLoS One

,

2013

, vol.

eight

 pg.

e53067

 

6

Markowitz

LE

,

Sternberg

M

,

Dunne

EF

,

McQuillan

G

,

Unger

ER

.

Seroprevalence of human being papillomavirus types vi, xi, 16, and eighteen in the United States: National Health and Diet Examination Survey 2003–2004

,

J Infect Dis

,

2009

, vol.

200

 (pg.

1059

-

67

)

7

Lehtinen

Chiliad

,

Kaasila

M

,

Pasanen

K

, et al.

Seroprevalence atlas of infections with oncogenic and non-oncogenic human being papillomaviruses in Finland in the 1980s and 1990s

,

Int J Cancer

,

2006

, vol.

119

 (pg.

2612

-

ix

)

eight

Castellsagué

Ten

,

Naud

P

,

Chow

SN

, et al.

Take chances of newly detected infections and cervical abnormalities in women seropositive for naturally acquired man papillomavirus blazon 16/18 antibodies: assay of the control arm of PATRICIA

,

2014

, vol.

210

 (pg.

517

-

34

)

9

Wentzensen

North

,

Rodriguez

Air-conditioning

,

Viscidi

R

, et al.

A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Report

,

J Infect Dis

,

2011

, vol.

204

 (pg.

94

-

102

)

10

Vaccarella

South

,

Franceschi

S

,

Clifford

GM

, et al.

Seroprevalence of antibodies confronting human papillomavirus (HPV) types 16 and 18 in 4 continents: the International Agency for Enquiry on Cancer HPV Prevalence Surveys

,

Cancer Epidemiol Biomarkers Prev

,

2010

, vol.

19

 (pg.

2379

-

88

)

xi

Guan

P

,

Howell-Jones

R

,

Li

North

, et al.

Human papillomavirus types in 115,789 HPV-positive women: a meta-assay from cervical infection to cancer

,

Int J Cancer

,

2012

, vol.

131

 (pg.

2349

-

59

)

12

Lu

B

,

Viscidi

RP

,

Wu

Y

, et al.

Prevalent serum antibody is not a mark of immune protection against conquering of oncogenic HPV16 in men

,

Cancer Res

,

2012

, vol.

72

 (pg.

676

-

85

)

thirteen

Clifford

GM

,

Shin

HR

,

Oh

JK

, et al.

Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, Southward Korea

,

Cancer Epidemiol Biomarkers Prev

,

2007

, vol.

sixteen

 (pg.

1874

-

9

)

fourteen

Hughes

JP

,

Garnett

GP

,

Koutsky

L

.

The theoretical population-level impact of a rubber human papilloma virus vaccine

,

2002

(pg.

631

-

ix

)

13

xv

Elbasha

EH

,

Dasbach

EJ

,

Insinga

RP

.

Model for assessing human papillomavirus vaccination strategies

,

Emerg Infect Dis

,

2007

, vol.

13

 (pg.

28

-

41

)

16

Barnabas

RV

,

Laukkanen

P

,

Koskela

P

,

Kontula

O

,

Lehtinen

M

,

Garnett

GP

.

Epidemiology of HPV 16 and cervical cancer in Republic of finland and the potential impact of vaccination: mathematical modelling analyses

,

PLoS Med

,

2006

, vol.

3

 pg.

e138

 

17

Choi

YH

,

Jit

Yard

,

Gay

N

,

Cox

A

,

Garnett

GP

,

Edmunds

WJ

.

Transmission dynamic modelling of the bear upon of human papillomavirus vaccination in the U.k.

,

Vaccine

,

2010

, vol.

28

 (pg.

4091

-

102

)

eighteen

Baussano

I

,

Garnett

One thousand

,

Segnan

N

,

Ronco

One thousand

,

Vineis

P

.

Modelling patterns of clearance of HPV-16 infection and vaccination efficacy

,

Vaccine

,

2011

, vol.

29

 (pg.

1270

-

7

)

19

Korostil

IA

,

Ali

H

,

Guy

RJ

,

Donovan

B

,

Law

MG

,

Regan

DG

.

Near elimination of genital warts in Australia predicted with extension of human being papillomavirus vaccination to males

,

Sex activity Transm Dis

,

2013

, vol.

xl

 (pg.

833

-

5

)

twenty

Taira

AV

,

Neukermans

CP

,

Sanders

GD

.

Evaluating human papillomavirus vaccination programs

,

Emerg Infect Dis

,

2004

, vol.

10

 (pg.

1915

-

23

)

21

Olsen

J

,

Jepsen

MR

.

Human being papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark

,

Int J Technol Assess Wellness Care

,

2010

, vol.

26

 (pg.

183

-

91

)

22

Vanni

T

,

Mendes Luz

P

,

Foss

A

,

Mesa-Frias

K

,

Legood

R

.

Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach

,

Vaccine

,

2012

, vol.

30

 (pg.

4866

-

71

)

23

Ribassin-Majed

Fifty

,

Lounes

R

,

Clemencon

S

.

Efficacy of vaccination against HPV infections to foreclose cervical cancer in French republic: present cess and pathways to improve vaccination policies

,

PLoS Ane

,

2012

, vol.

7

 pg.

e32251

 

24

Turner

HC

,

Baussano

I

,

Garnett

GP

.

Vaccinating women previously exposed to human papillomavirus: a toll-effectiveness analysis of the bivalent vaccine

,

PLoS One

,

2013

, vol.

8

 pg.

e75552

 

25

Kim

JJ

,

Andres-Beck

B

,

Goldie

SJ

.

The value of including boys in an HPV vaccination program: a cost-effectiveness analysis in a low-resources setting

,

Br J Cancer

,

2007

, vol.

97

 (pg.

1322

-

viii

)

26

Van de Velde

North

,

Brisson

Thou

,

Boily

MC

.

Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis

,

Vaccine

,

2010

, vol.

28

 (pg.

5473

-

84

)

27

Baussano

I

,

Elfstrom

KM

,

Lazzarato

F

, et al.

Type-specific human papillomavirus biological features: validated model-based estimates

,

PLoS One

,

2013

, vol.

viii

 pg.

e81171

 

28

Bogaards

JA

,

Xiridou

M

,

Coupe

VM

,

Meijer

CJ

,

Wallinga

J

,

Berkhof

J

.

Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for fourteen high-risk types of human papillomavirus

,

Am J Epidemiol

,

2010

, vol.

171

 (pg.

817

-

25

)

29

Zechmeister

I

,

Blasio

BF

,

Garnett

One thousand

,

Neilson

AR

,

Siebert

U

.

Cost-effectiveness analysis of homo papillomavirus-vaccination programs to prevent cervical cancer in Austria

,

Vaccine

,

2009

, vol.

27

 (pg.

5133

-

41

)

30

Johnson

HC

,

Elfstrom

KM

,

Edmunds

WJ

.

Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling arroyo

,

PLoS One

,

2012

, vol.

vii

 pg.

e49614

 

31

Tully

SP

,

Anonychuk

AM

,

Sanchez

DM

,

Galvani

AP

,

Bauch

CT

.

Time for alter? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada

,

Vaccine

,

2012

, vol.

30

 (pg.

425

-

35

)

32

Vanska

S

,

Auranen

K

,

Leino

T

, et al.

Impact of vaccination on 14 high-take chances HPV type infections: a mathematical modelling approach

,

PLoS One

,

2013

, vol.

8

 pg.

e72088

 

33

Baussano

I

,

Ronco

M

,

Segnan

North

,

French

One thousand

,

Vineis

P

,

Garnett

GP

.

HPV-16 infection and cervical cancer: modeling the influence of duration of infection and precancerous lesions

,

Epidemics

,

2010

, vol.

2

 (pg.

21

-

8

)

34

Baussano

I

,

Franceschi

S

,

Plummer

M

.

Infection manual and chronic disease models in the study of infection-associated cancers

,

Br J Cancer

,

2014

, vol.

110

 (pg.

seven

-

11

)

35

Garnett

GP

.

Function of herd immunity in determining the effect of vaccines against sexually transmitted disease

,

J Infect Dis

,

2005

, vol.

191

suppl 1

(pg.

S97

-

106

)

© The Author 2014. Published by Oxford University Printing on behalf of the Infectious Diseases Social club of America. All rights reserved. For Permissions, please email: journals.permissions@oup.com.